Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

239.92
-0.7300-0.30%
Post-market: 239.68-0.2400-0.10%16:36 EDT
Volume:747.99K
Turnover:178.86M
Market Cap:14.80B
PE:-54.31
High:244.55
Open:236.64
Low:234.53
Close:240.65
52wk High:248.60
52wk Low:124.06
Shares:61.70M
Float Shares:60.08M
Volume Ratio:0.86
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4176
EPS(LYR):-4.4176
ROE:-818.43%
ROA:-6.86%
PB:-78.13
PE(LYR):-54.31

Loading ...

The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com

Dow Jones
·
Dec 05, 2025

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026

Benzinga
·
Nov 28, 2025

European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading

MT Newswires Live
·
Nov 27, 2025

Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
Nov 26, 2025

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

TIPRANKS
·
Nov 26, 2025

FDA Extends Review of Ascendis Pharma’s TransCon CNP NDA to February 2026

Reuters
·
Nov 26, 2025

Ascendis Pharma annouces FDA extension for TransCon CN

TIPRANKS
·
Nov 26, 2025

Ascendis Pharma Price Target Maintained With a $220.00/Share by Wedbush

Dow Jones
·
Nov 18, 2025

Ascendis Pharma publishes results from ApproaCH Trial in JAMA Pediatrics

TIPRANKS
·
Nov 18, 2025

Ascendis Pharma Reports Positive Phase 3 Results for TransCon CNP in Children with Achondroplasia

Reuters
·
Nov 18, 2025

European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading

MT Newswires Live
·
Nov 18, 2025

Stock Track | Ascendis Pharma Soars 5.13% in Pre-Market Following Wells Fargo's Buy Rating

Stock Track
·
Nov 17, 2025

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

TIPRANKS
·
Nov 17, 2025

How Investors Are Reacting To Ascendis Pharma (ASND) Achieving First Positive Operating Income and Pooled Data Milestone

Simply Wall St.
·
Nov 15, 2025

Stock Track | Ascendis Pharma Soars 5.49% Amid Positive Analyst Sentiment and ADR Gains

Stock Track
·
Nov 15, 2025

Morgan Stanley Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Nov 13, 2025

Cantor Fitzgerald Sticks to Their Buy Rating for Ascendis Pharma (ASND)

TIPRANKS
·
Nov 13, 2025

Ascendis Pharma a/S : TD Cowen Raises Target Price to $325 From $227

THOMSON REUTERS
·
Nov 13, 2025

Stock Track | Ascendis Pharma Plunges 9.15% After-Hours on Wider-Than-Expected Q3 Loss Despite Revenue Growth

Stock Track
·
Nov 13, 2025

Earnings Flash (ASND) Ascendis Pharma Posts Q3 Revenue 213.6M Euros, vs. FactSet Est of 213.2M Euros

MT Newswires Live
·
Nov 13, 2025